Nurse-initiated protocols in the emergency department management of pediatric oncology patients with fever and suspected neutropenia: a scoping review protocol

Objective: To provide an overview of the evidence for nurse-initiated protocol in the emergency management of pediatric oncology patients with fever and neutropenia is suspected.
Introduction: febrile neutropenia in pediatric oncology patients pose a significant burden of increased morbidity and mortality. Prompt, efficient emergency care and rapid administration of antibiotics within 60 minutes of presentation to the hospital is required to prevent clinical deterioration and reduce the rate of entry of intensive care and death.

efficient emergency department care delivery is influenced by modern challenges, such as increasing user demand, limited resources, and lack of flow. In response to this, in order to expedite the provision of care, practice guidelines have been developed to include nurse initiated protocols that guide nurses to initiate investigations that have been specifically and intervention for patients meet certain criteria. Febrile neutropenic pediatric patients may be certain groups that can benefit from nurse-initiated protocol because of the critical nature of the required treatment time.

Inclusion criteria: Review of scoping will consider the literature that reports the nurse initiated protocols in the management of pediatric oncology febrile neutropenia in patients suspected of emergency department setting.
Methods: JBI methodology for scoping review will guide the review process. English literature from 2000 to the present will be sought in Embase, Medline, Scopus, Emcare, CINAHL Plus and gray literature in Google Scholar, Open Gray, and global Theses. critical assessment will be performed. Tabular summary and accompanying narrative will present information extracted in tune with this review evidence and objective questions. In recognition of the increasing incidence and mortality of cancer in low and medium settings resources, as well as the increasingly international profile membership, ASCO has prioritized efforts to increase its involvement on a global level.

Among the recommendations in the 2016 report include Global Oncology Leadership Task Force ASCO ASCO is that the Board of Directors should promote the recognition of global oncology academic field. The report recommends that the ASCO could serve a role in the transition of the global oncology field largely informal voluntary activity to a more formal discipline with a strong research and training components are well defined. As a result of this recommendation, in 2017, ASCO shaping global Oncology Academic Task Force (AGOTF) to guide the ASCO contribution to inaugurate global oncology field.

Patient perception Telehealth Service for Breast and Gynecologic Oncology Care for Pandemic COVID-19: Survey based study A Single Center

Before the coronavirus disease in 2019 (COVID-19) pandemic, telehealth is rarely used for oncology care in the metropolitan area. New York City based breast outpatient clinics / major gynecological cancer we are given a 18-question survey to patients from March to June 2020, to assess the perception of the usefulness of telehealth medicine. Of the 622 patients, 215 (35%) completed the survey, and of the 215 respondents, 74 (35%) have participated in telehealth visits. We evaluated the use of telehealth services using a validated Technology Service User Acceptance Questionnaire.

Sixty-eight patients (92%) reported that telehealth services save them time, 54 (73%) reported telehealth improved access to treatment, and 58 (82%) reported telehealth improve their health. Overall, 67 (92%) of the patients said they were satisfied with the use of telehealth services for oncology care during the 19th COVID pandemic. telehealth services should be carefully adopted as an adjunct in the clinical care of patients with cancer.

glioblastoma post-operative imaging in the neuro-oncology: current UK practice (GIN CUP study)

Purpose: MRI remains the preferred imaging investigation for glioblastoma. neuroimaging appropriate and timely follow-up period was considered important in making management decisions. There is a shortage of evidence-based information on the current UK, European and international guidelines on the timing and type of neuroimaging after surgical treatment of early nerves optimal. The study assessed the current imaging practice between central neuro-oncology UK, so as to provide basic data and inform future practice.
Methods: Leading neuro-oncology, neuroradiologist and neurosurgeon of any UK neuro-oncology centers were invited to complete an online survey. Participants were asked about current practices and ideal imaging after initial treatment.

Results: Ninety-two participants from around 31 neuro-oncology centers completed the survey (response rate of 100%). Most centers routinely performed early postoperative MRI (87%, 27/31), while only a third of pre-radiotherapy MRI (32%, 10/31). Number and timing of routine scans performed during adjuvant TMZ treatment varies between centers. At the end of the adjuvant, most centers do MRI (71%, 22/31), followed by monitoring scan 3 monthly intervals (81%, 25/31). Additional short-interval imaging is done in cases which may pseudoprogression in most centers (71%, 22/31). Routine use of advanced imaging is rare; However, the addition of advanced sequence is the most popular suggestions for ideal imaging practice, followed by a time change EPMRI.

TAT Peptide
abx266559-1ml	Abbexa	1 ml	EUR 287.5

TAT Peptide
abx266559-200l	Abbexa	200 µl	EUR 237.5

TAT peptide
TP1451-10mg	TargetMol Chemicals	10mg	Ask for price
Description: TAT peptide

TAT peptide
TP1451-1g	TargetMol Chemicals	1g	Ask for price
Description: TAT peptide

TAT peptide
TP1451-1mg	TargetMol Chemicals	1mg	Ask for price
Description: TAT peptide

TAT peptide
TP1451-50mg	TargetMol Chemicals	50mg	Ask for price
Description: TAT peptide

TAT peptide
TP1451-5mg	TargetMol Chemicals	5mg	Ask for price
Description: TAT peptide

TAT peptide
MBS5763704-10mg	MyBiosource	10mg	EUR 765

TAT peptide
MBS5763704-1mg	MyBiosource	1mg	EUR 190

TAT peptide
MBS5763704-5mg	MyBiosource	5mg	EUR 485

TAT peptide
MBS5763704-5x10mg	MyBiosource	5x10mg	EUR 3305

Peptide E / 3200-Dalton Adrenal Enkephalin-Containing Peptide (Bovine)
024-57	PHOENIX PEPTIDE	200 μg	EUR 86.4

PSTAIR Peptide
070-61	PHOENIX PEPTIDE	500 μg	EUR 129.6

PGMtide Peptide
040-69	PHOENIX PEPTIDE	100 μg	EUR 316.44

Adjuvant Peptide
070-05	PHOENIX PEPTIDE	500 μg	EUR 36.72

Peptide-epsilon
058-22	PHOENIX PEPTIDE	500 μg	EUR 114.48

Delicious Peptide
070-21	PHOENIX PEPTIDE	5 mg	EUR 160.92

proSex peptide (20-55)
040-30	PHOENIX PEPTIDE	100 μg	EUR 355.32

proSex peptide (28-55)
040-31	PHOENIX PEPTIDE	100 μg	EUR 282.96

proSex peptide (40-55)
040-32	PHOENIX PEPTIDE	100 μg	EUR 214.92

Bombinin-Like Peptide 1 amide / prepro-Bombinin-Like Peptide (44-70) amide / prepro-Bombinin-Like Peptide (107-133) amide
007-60	PHOENIX PEPTIDE	100 μg	EUR 214.92

Peptide F-9
038-06	PHOENIX PEPTIDE	200 μg	EUR 58.32

Sturgeon Peptide (137-158)
021-94	PHOENIX PEPTIDE	100 μg	EUR 177.12

Peptide Lv (Rat)
008-73	PHOENIX PEPTIDE	100 μg	EUR 469.8

NGR Peptide 1
025-74	PHOENIX PEPTIDE	200 μg	EUR 184.68

Anorexigenic Peptide
070-10	PHOENIX PEPTIDE	5 mg	EUR 86.4

GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human)
029-03	PHOENIX PEPTIDE	500 μg	EUR 114.48

GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human)
029-04	PHOENIX PEPTIDE	100 μg	EUR 114.48

GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human)
029-05	PHOENIX PEPTIDE	20 μg	EUR 267.84

GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human)
029-06	PHOENIX PEPTIDE	100 μg	EUR 114.48

Bid BH3 peptide
025-87	PHOENIX PEPTIDE	1 mg	EUR 170.64

AF-16 Peptide
033-44	PHOENIX PEPTIDE	200 μg	EUR 214.92

Peptide Lv (Human)
008-71	PHOENIX PEPTIDE	100 μg	EUR 405

Peptide Lv (Mouse)
008-72	PHOENIX PEPTIDE	100 μg	EUR 469.8

GnRH Associated Peptide (GAP) (1-13) / Gn-RH Precursor Peptide (14-26) (Rat)
029-08	PHOENIX PEPTIDE	200 μg	EUR 64.8

Peptide B (Bovine)
024-56	PHOENIX PEPTIDE	200 μg	EUR 81

Peptide F (Bovine)
024-58	PHOENIX PEPTIDE	200 μg	EUR 114.48

ExE peptide M3mP6
064-33	PHOENIX PEPTIDE	200 μg	EUR 244.08

PLP Peptide (103-116) (Bovine)
070-14	PHOENIX PEPTIDE	5 mg	EUR 140.4

FMRF-Like Peptide
047-32	PHOENIX PEPTIDE	1 mg	EUR 27

Joining Peptide (Rat)
047-91	PHOENIX PEPTIDE	200 μg	EUR 160.92

Growth Hormone-Releasing Peptide-Related Peptide-1 (fGRP-RP-1) (Frog)
048-80	PHOENIX PEPTIDE	500 μg	EUR 177.12

Growth Hormone-Releasing Peptide-Related Peptide-2 (fGRP-RP-2) (Frog)
048-81	PHOENIX PEPTIDE	200 μg	EUR 214.92

Growth Hormone-Releasing Peptide-Related Peptide-3 (fGRP-RP-3) (Frog)
048-82	PHOENIX PEPTIDE	200 μg	EUR 214.92

Peptide T (4-8)
057-04	PHOENIX PEPTIDE	500 μg	EUR 64.8

Peptide T (5-8)
057-05	PHOENIX PEPTIDE	500 μg	EUR 64.8

Vasonatrin Peptide (VNP)
005-47	PHOENIX PEPTIDE	200 μg	EUR 214.92

Opioid Peptide Library
L-002	PHOENIX PEPTIDE	58 peptides	EUR 2691.36

Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine)
064-01	PHOENIX PEPTIDE	200 μg	EUR 108

Heparin Binding Peptide
025-47	PHOENIX PEPTIDE	500 μg	EUR 102.6

Gastrin Related Peptide
027-09	PHOENIX PEPTIDE	5 mg	EUR 73.44

PGMtide Control Peptide
040-70	PHOENIX PEPTIDE	100 μg	EUR 316.44

Growth Blocking Peptide
046-92	PHOENIX PEPTIDE	100 μg	EUR 255.96

Neuron Specific Peptide
047-55	PHOENIX PEPTIDE	200 μg	EUR 140.4

Obesity Peptide Library
L-003	PHOENIX PEPTIDE	160 peptides	EUR 7267.32

[D-Ala1]-Peptide T
057-02	PHOENIX PEPTIDE	5 mg	EUR 282.96

Peptide YY (PYY) (Human)
059-01	PHOENIX PEPTIDE	200 μg	EUR 119.88

Eledoisin Related Peptide
046-04	PHOENIX PEPTIDE	5 mg	EUR 58.32

proSex peptide (28-55) - EIA Kit
EK-040-31	PHOENIX PEPTIDE	96 wells	EUR 603.72

Peptide F 1 (Lobster)
047-62	PHOENIX PEPTIDE	500 μg	EUR 73.44

Morphine Tolerance Peptide
050-13	PHOENIX PEPTIDE	1 mg	EUR 102.6

Phosphate Acceptor Peptide
058-24	PHOENIX PEPTIDE	500 μg	EUR 73.44

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human)
064-07	PHOENIX PEPTIDE	200 μg	EUR 114.48

Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia brasiliana)
047-39	PHOENIX PEPTIDE	200 μg	EUR 444.96

Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia brasiliana)
047-40	PHOENIX PEPTIDE	500 μg	EUR 214.92

Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia californica)
047-42	PHOENIX PEPTIDE	200 μg	EUR 444.96

Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia californica)
047-43	PHOENIX PEPTIDE	500 μg	EUR 214.92

FGL Peptide - Cy3 Labeled
FC3-073-36	PHOENIX PEPTIDE	1 nmol	EUR 672.84

FGL Peptide - Cy5 Labeled
FC5-073-36	PHOENIX PEPTIDE	1 nmol	EUR 756

FGL Peptide - FAM Labeled
FG-073-36A	PHOENIX PEPTIDE	1 nmol	EUR 405

Pedal Peptide (Pep) (Aplysia)
047-61	PHOENIX PEPTIDE	500 μg	EUR 177.12

ExE peptide M3mP6 mutant
064-35	PHOENIX PEPTIDE	200ug	EUR 234.36

ExE peptide M3mP6 mutant
064-37	PHOENIX PEPTIDE	200ug	EUR 234.36

FGL Peptide - FITC Labeled
FG-073-36B	PHOENIX PEPTIDE	1 nmol	EUR 405

AF-16 Peptide - Antibody
H-033-44	PHOENIX PEPTIDE	100 μl	EUR 336.96

Schizophrenia Related Peptide
047-79	PHOENIX PEPTIDE	5 mg	EUR 44.28

Insulin B (22-25) Peptide
035-08	PHOENIX PEPTIDE	5 mg	EUR 86.4

Eosinophilotactic Peptide (AGSE)
070-28	PHOENIX PEPTIDE	5 mg	EUR 27

Eosinophilotactic Peptide (VGSE)
070-29	PHOENIX PEPTIDE	5 mg	EUR 27

Cell Penetrating ARF Peptide (26-44)
068-56	PHOENIX PEPTIDE	500 μg	EUR 640.44

Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - RIA Kit
RK-064-01	PHOENIX PEPTIDE	125 tubes	EUR 932.04

FGL Peptide - Biotin Labeled
B-073-36	PHOENIX PEPTIDE	20 μg	EUR 405

Peptide F (Bovine) - Antibody
H-024-58	PHOENIX PEPTIDE	50 μl	EUR 238.68

Brain Peptide (Bees) Library
L-007	PHOENIX PEPTIDE	51 peptides	EUR 6456.24

TAT Derivative, R9-Tat
068-27	PHOENIX PEPTIDE	500 μg	EUR 370.44

Gastrointestinal Peptide Library
L-006	PHOENIX PEPTIDE	200 peptides	EUR 7267.32

Peptide R / CXCR4 Antagonist
030-25	PHOENIX PEPTIDE	200 μg	EUR 203.04

PGMtide Peptide - Cy3 Labeled
FC3-040-69	PHOENIX PEPTIDE	1 nmol	EUR 925.56

PGMtide Peptide - FAM Labeled
FG-040-69A	PHOENIX PEPTIDE	5 nmol	EUR 537.84

[D-Arg14, D-Arg15]-MGF Peptide amide / C-terminal peptide of IGF-1 Ec amide
033-34	PHOENIX PEPTIDE	100 μg	EUR 177.12

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Antibody
H-064-07	PHOENIX PEPTIDE	50 μl	EUR 238.68

[D-Ala1]-Peptide T amide
057-03	PHOENIX PEPTIDE	500 μg	EUR 140.4

Peptide F (Bovine) - RIA Kit
RK-024-58	PHOENIX PEPTIDE	125 tubes	EUR 932.04

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - RIA Kit
RK-064-07	PHOENIX PEPTIDE	125 tubes	EUR 932.04

Catch-Relaxing Peptide (CARP)
047-20	PHOENIX PEPTIDE	1 mg	EUR 199.8

Calmodulin Binding Peptide 1
070-17	PHOENIX PEPTIDE	20 μg	EUR 214.92

FGL Peptide - Rhodamine Labeled
FR-073-36	PHOENIX PEPTIDE	1 nmol	EUR 537.84

Peptide-Depleted Plasma (Rat)
MB-099-02	PHOENIX PEPTIDE	2 ml	EUR 119.88

Glycogenolysis-Inhibiting Peptide
023-63	PHOENIX PEPTIDE	500 μg	EUR 177.12

Anti-Inflammatory Peptide 1
004-01	PHOENIX PEPTIDE	200 μg	EUR 27

Anti-Inflammatory Peptide 2
004-02	PHOENIX PEPTIDE	200 μg	EUR 27

Anti-Inflammatory Peptide 3
004-03	PHOENIX PEPTIDE	200 μg	EUR 27

Urokinase-Derived Peptide A6
025-12	PHOENIX PEPTIDE	500 μg	EUR 129.6

PGMtide Peptide - Biotin Labeled
B-040-69	PHOENIX PEPTIDE	20 μg	EUR 537.84

Peptide 34 / GPR-54 Agonist
048-94	PHOENIX PEPTIDE	200 μg	EUR 114.48

FGL Peptide - I-125 Labeled
T-073-36	PHOENIX PEPTIDE	10 μCi	EUR 1145.88

Peptide-Depleted Plasma (Human)
MB-099-01	PHOENIX PEPTIDE	2 ml	EUR 119.88

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - FAM Labeled
FG-064-07A	PHOENIX PEPTIDE	1 nmol	EUR 336.96

Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - I-125 Labeled
T-064-01	PHOENIX PEPTIDE	10 μCi	EUR 1145.88

F3 Peptide / HMGN2 Fragment 3
004-12	PHOENIX PEPTIDE	100 μg	EUR 214.92

Antimicrobial Trp-rich peptide
004-05	PHOENIX PEPTIDE	100 μg	EUR 140.4

Fibronectin CS1 Peptide (EILDVPST)
025-20	PHOENIX PEPTIDE	500 μg	EUR 86.4

Myosin Kinase Inhibiting Peptide
058-20	PHOENIX PEPTIDE	500 μg	EUR 50.76

Peptide YY (PYY) (3-36) (Human)
059-02	PHOENIX PEPTIDE	200 μg	EUR 102.6

PGMtide Peptide - Rhodamine Labeled
FR-040-69	PHOENIX PEPTIDE	5 nmol	EUR 604.8

Anti-Angiogenic Peptide Library
L-008A	PHOENIX PEPTIDE	88 peptides	EUR 6067.44

Peptide YY (PYY) (Human) - Antibody
H-059-01	PHOENIX PEPTIDE	100 μl	EUR 469.8

Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - Purified IgG Antibody
G-064-01	PHOENIX PEPTIDE	400 μg	EUR 438.48

Peptide A / p60v-src (137-157)
058-21	PHOENIX PEPTIDE	500 μg	EUR 135

pro-Opionmelanocortin / J Peptide
022-22	PHOENIX PEPTIDE	200 μg	EUR 177.12

Cancer-Targeting Peptide Library
L-015	PHOENIX PEPTIDE	289 peptides	EUR 7253.28

C28 optimized peptide 6 (Human)
073-82	PHOENIX PEPTIDE	100 μg	EUR 235.44

Kemptide / Phosphate Acceptor Peptide
058-16	PHOENIX PEPTIDE	500 μg	EUR 36.72

Bioactive Secretory Peptide Library
L-009	PHOENIX PEPTIDE	1016 peptides	EUR 31350.24

Peptide YY (PYY) (Human) - EIA Kit
EK-059-01	PHOENIX PEPTIDE	96 wells	EUR 617.76

Peptide YY (PYY) (Human) - RIA Kit
RK-059-01	PHOENIX PEPTIDE	125 tubes	EUR 814.32

Galanin-Like Peptide (GALP) (Rat)
026-52	PHOENIX PEPTIDE	100 μg	EUR 282.96

PACAP-Related Peptide (PRP) (Rat)
052-11	PHOENIX PEPTIDE	200 μg	EUR 86.4

Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - I-125 Labeled
T-064-07	PHOENIX PEPTIDE	10 μCi	EUR 1145.88

Crustacean Cardioactive Peptide (CCAP)
047-24	PHOENIX PEPTIDE	500 μg	EUR 86.4

Virus Replication Inhibiting Peptide
070-85	PHOENIX PEPTIDE	5 mg	EUR 160.92

Pri Peptide from sORF pri RNA
069-77	PHOENIX PEPTIDE	200 μg	EUR 160.92

Alzheimer Fingerprint Peptide Library
L-011	PHOENIX PEPTIDE	85 peptides	EUR 6529.68

Annexin A1 Binding Peptide, IF7CRR
025-72	PHOENIX PEPTIDE	200 μg	EUR 184.68

Conclusion: Variations in neuroimaging practice there after the initial treatment of glioblastoma in the United Kingdom. Multicenter, longitudinal, prospective trial is needed to determine the optimal imaging schedule for the assessment.